Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
- 15 July 2008
- journal article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 5 (10) , 574-576
- https://doi.org/10.1038/ncponc1180
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancerJournal of Clinical Oncology, 2007
- 600: Intermittent Androgen Deprivation in Patients with PSA-Relapse after Radical Prostatectomy - Final Results of a European Randomized Prospective Phase-III Clinical Trial Auo Study AP 06/95, EC 507Journal of Urology, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation TherapyJournal of Clinical Oncology, 2006
- Phase III intermittent MAB vs continuous MABJournal of Clinical Oncology, 2006
- Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal AblationThe Oncologist, 2003
- Intermittent Versus Continuous Total Androgen Blockade in the Treatment of Patients with Advanced Hormone-Naive Prostate Cancer: Results of a Prospective Randomized Multicenter TrialClinical Prostate Cancer, 2002
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000
- Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour modelThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer, 1993